Yesodot Eitanim: The Rehovot financing test after the maturity extension
The Rehovot maturity extension to May 19, 2026 bought Yesodot Eitanim time, but it did not remove the bottleneck. At the end of 2025 there was still no signed project-finance agreement, expected gross margin had fallen to 2.3%, and sensitivity to price and cost was already larger than the profit still left to recognize.
Why Rehovot Matters
The main article argued that the stronger 2025 equity base did not solve the financing and execution test. Rehovot is where that test appears in its cleanest form. There is land for a 39-unit project and an expected revenue base of ILS 175.3 million, but there is also roughly ILS 40.8 million of land financing that was extended again to May 19, 2026, while by the end of 2025 there was still no signed project-finance agreement. This is not just another maturity push. It is a sign that the project has not yet moved from land-stage financing into a more stable funding structure.
What makes Rehovot an especially clear bottleneck is the timetable. Construction is still planned to begin in the third quarter of 2026, and marketing is also planned to begin in the third quarter of 2026, both after the new loan maturity date. There are still no contractor agreements either. In plain terms, the extension does not carry the project into its planned operating window. It only buys more time to reach the next financing point.
The Project at the End of 2025
| Checkpoint | Figure | Why it matters |
|---|---|---|
| Project scale | 39 units | This is meaningful relative to the company’s size, but still an early-stage project |
| Expected revenue and cost | ILS 175.291 million of expected revenue versus ILS 171.239 million of expected cost | The remaining profit cushion for the full project is very thin |
| Expected gross profit | ILS 4.049 million, or 2.3% | A margin this narrow turns even small deviations into a material issue |
| Accumulated cost versus remaining cost | ILS 82.543 million invested by year-end 2025, with ILS 88.700 million still left to complete | A large part of the project’s economic journey is still ahead |
| Sales pace | One unit signed by year-end 2025, equal to a 2% sales rate, plus 2 more contracts after period-end | The sales base is still too narrow for a project that has to move into full financing |
| Land financing | Roughly ILS 40.8 million, due May 19, 2026 | The financing timeline remains short relative to the operating timeline |
| Project finance status | No signed project-finance agreement yet | This is the main practical missing piece right now |
That chart sharpens why Rehovot is not just another land project waiting patiently in the background. Expected revenue barely changed between 2024 and 2025, but costs kept rising. As a result, expected gross profit fell from ILS 10.335 million to ILS 4.049 million, and expected margin dropped to 2.3%. Financing therefore cannot be analyzed on its own. It now sits on project economics that have already lost most of their safety buffer.
What the Maturity Extension Actually Means
The February 2026 immediate report was very direct: the maturity of the Rehovot land financing was extended to May 19, 2026, with no change in the other financing terms. That is the key line in the report. When only the date moves, the basic structure has not been solved. It has only been postponed.
The annual report fills in the missing details around that sentence. The land financing is presented as short-term debt, with interest at prime plus a spread of 1.2% to 1.7%, secured by a first-ranking fixed charge without amount limit over the land rights. In addition, the financing is explicitly described as not non-recourse, and the company’s shareholders together with the partner’s shareholders guarantee the full obligations to the bank. At the same time, the note on pledges again records a secured balance of ILS 40.808 million tied to the Rehovot land.
That leads to a simple but important conclusion. The maturity extension did not change the risk layer. It did not convert the loan into formal project finance, it did not reduce the security package, it did not isolate the risk away from the shareholder layer, and it did not solve the fact that the project is still being carried on land financing rather than execution-stage financing.
There is also one detail that looks small but says a lot. The project financing table does not list central financial covenants, which sounds comforting on the surface. But in the absence of numeric covenant pressure, the focus shifts even more to whether the project can actually move into its next stage on time. When the new maturity date is May 2026 while construction and marketing are only planned for the third quarter, what is missing is not a few extra weeks of air. What is missing is a real transition in the financing structure.
The Profit Cushion Is Already Too Thin
The Rehovot financing test is harder because the project no longer sits on a wide gross-profit cushion. At the end of 2025, the project had only ILS 4.052 million of expected gross profit still left to recognize. Against that figure, the company’s own sensitivity table looks almost disproportionate: a 5% decline in selling prices for unsigned areas cuts ILS 8.765 million from the expected gross profit still left to recognize, while a 5% rise in construction cost cuts another ILS 8.562 million.
That chart is the core of the read. The issue is not only that the financing is short. The issue is that the short financing sits on a project where even a moderate deviation in price or cost can wipe out the profit cushion that is still left. So even if the bank agreed to one more extension, that does not necessarily mean the risk has eased. It may simply have been deferred to a nearer checkpoint.
Sales status does not yet provide a strong enough counterweight. By the end of 2025 only one contract had been signed, equal to 2% of the project, and cumulative revenue from signed contracts stood at ILS 4.152 million. After period-end, another 2 contracts were signed, but even that still leaves Rehovot at a stage where most of the thesis rests on future sales rather than on a broad base of already signed demand.
That matters even more because by the end of 2025 there were still 38 unsigned units, 5,986 unsold square meters, and ILS 80.587 million of attributed cost tied to areas that still had no binding contracts. In other words, most of the project’s economics remain open at exactly the point where the margin cushion has become narrow.
What Has to Happen Next
First: Rehovot has to bridge the gap between May 2026 and the third quarter of 2026. As long as the maturity date arrives before the planned start of construction and marketing, the latest extension remains an interim station rather than a solution.
Second: the company has to sign a project-finance agreement. At the end of 2025 this still had not happened, which means the funding source carrying the land has not yet been replaced by a structure suited to the project’s next stage.
Third: the sales base has to expand well beyond the 3 units signed by the report date. In a project whose expected gross margin has already fallen to 2.3%, financing progress without stronger commercial backing can still remain fragile.
Fourth: cost estimates have to stop rising. Over the last two years, expected cost increased from ILS 155.172 million to ILS 171.239 million while expected revenue barely moved. If 2026 brings another round like that, Rehovot will move from being mainly a financing test to being a project whose economics themselves become the central problem.
Conclusion
Rehovot is a good financing test precisely because it does not hide behind a broader story. There is a land loan that was extended again without any change in terms, there is still no signed project-finance agreement, and the project is supposed to begin moving operationally only after the new maturity date. That alone would already justify attention.
What makes the issue more material is the interaction with the project’s economics. Expected revenue barely changed, costs kept moving up, expected gross margin fell to 2.3%, and the sensitivity analysis shows that even a modest deviation in price or cost already wipes out the remaining profit. So Rehovot is not only about debt rollover. It is a test of whether Yesodot Eitanim can move a project from short land-stage financing into proper project finance and execution without losing most of its economic value along the way.
Current thesis: the Rehovot maturity extension bought time, but it did not solve the bottleneck. Until project finance is signed and a wider sales base is built, the project remains both a financing test and an economics test.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.